Studies have linked GLP-1 medications to various eye conditions, some of which may lead to vision loss. Despite these ...

This study is significant as it explores a potential new treatment option for diabetic retinopathy, a leading cause of blindness. The intervention tested was EYP-1901, a Tyrosine Kinase Inhibitor, ...

British number one blind golfer Billy McAllister recalls his journey in the sport after completely losing his eyesight in ...

Macular edema (ME), a leading cause of central vision loss, is often treated with anti-vascular endothelial growth factor ...

GLP-1 receptor agonists linked to modestly increased risk for incident DR, but tied to reduced risk for certain complications of DR.

Microaneurysm (MA) turnover increases with the progression of nonproliferative diabetic retinopathy (NPDR) and is correlated with presence of intraretinal microvascular abnormalities (IRMAs), ...

A large study of over 185,000 adults with type 2 diabetes found that GLP-1 receptor agonist use was linked to a slight ...

Fully autonomous screening for diabetic retinopathy is coming to pharmacies and other locations through a strategic ...

More evidence shows a risk between GLP-1 drugs and vision risks. A study in JAMA Network Open adds more evidence linking ...

Aging brings wisdom, experience, and often, a host of changes — including those that affect our vision. "By the time most people reach their forties, the eye begins to undergo physiological ...

An Editorial in The Lancet Neurology emphasised that rigorous prospective studies are essential to develop safe and ethical artificial intelligence (AI) tools for brain health.1 Yet, what usually ...

The findings of this study suggest that semaglutide was not associated with an increased risk of eye disorders or diabetic retinopathy. Despite the fact that an association between semaglutide ...